tadalafil has been researched along with Impotence, Arteriogenic in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arslan, E; Çiftçi, H; Dokumacı, DŞ; Kati, B; Kırteke, A; Pelit, ES; Tunçtekin, A; Yağmur, İ; Yeni, E | 1 |
| Albayrak, S; Bayraktar, Z | 1 |
| Aversa, A; Balercia, G; Bocchio, M; Boscaro, M; Carani, C; Corona, G; Fabbri, A; Foresta, C; Forti, G; Francavilla, S; Granata, AR; Gravina, GL; Isidori, AM; Jannini, EA; Lenzi, A; Maggi, M; Mansani, R; Palego, P; Spera, G; Vetri, M | 1 |
| Porst, H | 1 |
| Abdo, CH; Gallagher, GL; Glina, S; Hernandez-Serrano, R; Lenero, E; Rampazzo, C; Rubio-Aurioles, E; Sotomayor, M; West, TM | 1 |
| Shindel, AW | 1 |
| Büttner, H; Hell-Momeni, K; Porst, H | 1 |
| Davies, KP; Friedman, A; Friedman, J; Han, G; Kuppam, DS; Melman, A; Tar, M | 1 |
| Althof, SE; Belger, M; Buvat, J; Fugl-Meyer, AR; Gutkin, SW; Stothard, DR | 1 |
| Katz, A | 1 |
| Chung, E | 1 |
| Pan, W; Wu, J; Zhang, HL | 1 |
| Calogero, AE; Condorelli, R; D'Agata, R; La Vignera, S; Vicari, E | 1 |
| La Vignera, S | 1 |
| Corona, G; Fusco, F; Mondaini, N; Razzoli, E; Rossi, A; Ungar, A | 1 |
| Celso, M; Del Popolo, G; Lombardi, G; Mencarini, M; Nelli, F | 1 |
| Chen, B; Chen, Z; Hu, JL; Huang, YR; Ma, Y; Wang, HX; Wang, YX; Xia, JG; Yang, Y | 1 |
| Anderson, PC; Arya, M; Gommersall, L; Hayne, D; Patel, HR | 1 |
| Forgue, ST; Rapado, J; Staab, A; Tillmann, C; Trocóniz, IF | 1 |
| Ferrini, MG; Gonzalez-Cadavid, N; Kovanecz, I; Rajfer, J; Rambhatla, A; Sanchez, S; Vernet, D | 1 |
4 review(s) available for tadalafil and Impotence, Arteriogenic
| Article | Year |
|---|---|
[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil].
Topics: Biological Availability; Carbolines; Dose-Response Relationship, Drug; Drug Administration Schedule; Half-Life; Humans; Impotence, Vasculogenic; Long-Term Care; Male; Metabolic Clearance Rate; Patient Satisfaction; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Pilot Projects; Randomized Controlled Trials as Topic; Tadalafil | 2009 |
Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
Topics: Algorithms; Carbolines; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypertension; Imidazoles; Impotence, Vasculogenic; Male; Men's Health; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrimidines; Risk Factors; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2011 |
Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
Topics: Carbolines; Central Nervous System Diseases; Clinical Trials as Topic; Humans; Imidazoles; Impotence, Vasculogenic; Male; Multiple Sclerosis; Parkinson Disease; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Spinal Dysraphism; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2012 |
New phosphodiesterase inhibitors in the treatment of erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Diabetes Complications; Drug Interactions; Humans; Imidazoles; Impotence, Vasculogenic; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2004 |
6 trial(s) available for tadalafil and Impotence, Arteriogenic
| Article | Year |
|---|---|
Efficacy and safety of combination of tadalafil and aspirin versus tadalafil or aspirin alone in patients with vascular erectile dysfunction: a comparative randomized prospective study.
Topics: Adult; Aspirin; Drug Combinations; Humans; Impotence, Vasculogenic; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Platelet Aggregation Inhibitors; Prospective Studies; Tadalafil; Treatment Outcome | 2019 |
The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction.
Topics: Analysis of Variance; Carbolines; Confidence Intervals; Cross-Over Studies; Health Surveys; Humans; Imidazoles; Impotence, Vasculogenic; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Risk; Sildenafil Citrate; Statistics as Topic; Sulfones; Tadalafil; Time Factors; Triazines; Vardenafil Dihydrochloride | 2009 |
Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil: a geographical comparison from a single arm, open-label study.
Topics: Analysis of Variance; Asia; Australia; Carbolines; Coitus; Confidence Intervals; Europe; Geography; Health Status Indicators; Humans; Impotence, Vasculogenic; Latin America; Male; Middle Aged; Middle East; New Zealand; Patient Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Time Factors | 2009 |
Sexual satisfaction in men with erectile dysfunction: correlates and potential predictors.
Topics: Adult; Aged; Carbolines; Dose-Response Relationship, Drug; Humans; Impotence, Vasculogenic; Logistic Models; Male; Middle Aged; Patient Satisfaction; Penile Erection; Phosphodiesterase Inhibitors; Tadalafil | 2010 |
Pharmaco-induced erections for penile color-duplex ultrasound: oral PDE5 inhibitors or intracavernosal injection?
Topics: Administration, Oral; Adult; Arteries; Carbolines; Humans; Impotence, Vasculogenic; Injections; Male; Middle Aged; Papaverine; Penile Erection; Penis; Phosphodiesterase 5 Inhibitors; Piperazines; Prospective Studies; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Ultrasonography, Doppler, Color; Vasodilator Agents | 2012 |
Tadalafil population pharmacokinetics in patients with erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Aged; Area Under Curve; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Impotence, Vasculogenic; Male; Middle Aged; Models, Biological; Tadalafil; Vasodilator Agents | 2007 |
11 other study(ies) available for tadalafil and Impotence, Arteriogenic
| Article | Year |
|---|---|
Carotid artery intima-media thickness can predict the response of patients with erectile dysfunction to phosphodiesterase 5 inhibitors.
Topics: Adult; Aged; Carotid Intima-Media Thickness; Humans; Impotence, Vasculogenic; Male; Middle Aged; Penis; Phosphodiesterase 5 Inhibitors; Prognosis; Prospective Studies; ROC Curve; Tadalafil; Turkey; Ultrasonography, Doppler, Color | 2019 |
[Once daily therapy of erectile dysfunction. "Flexible love life without time constraints"].
Topics: Carbolines; Drug Administration Schedule; Humans; Impotence, Vasculogenic; Long-Term Care; Male; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Tadalafil | 2009 |
2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class.
Topics: Carbolines; Clitoris; Education, Medical, Continuing; Female; Hearing Disorders; Humans; Imidazoles; Impotence, Vasculogenic; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sexual Dysfunctions, Psychological; Sexuality; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2009 |
Nanoparticles as a novel delivery vehicle for therapeutics targeting erectile dysfunction.
Topics: Administration, Cutaneous; Age Factors; Animals; Carbolines; Drug Delivery Systems; Feasibility Studies; Free Radical Scavengers; Impotence, Vasculogenic; Male; Nanocapsules; Nitric Oxide; Penile Erection; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Protease Inhibitors; Protein Precursors; Rats; Rats, Sprague-Dawley; Salivary Proteins and Peptides; Tadalafil | 2010 |
Erectile dysfunction.
Topics: Blood Glucose; Carbolines; Cardiovascular Diseases; Cholesterol; Erectile Dysfunction; Humans; Imidazoles; Impotence, Vasculogenic; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2010 |
Failure of PDE5 inhibitor use: a case of nonresponder? (CME).
Topics: Carbolines; Diagnosis, Differential; Humans; Imidazoles; Impotence, Vasculogenic; Male; Middle Aged; Patient Care Team; Penile Erection; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Referral and Consultation; Risk Factors; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Failure; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2010 |
Efficacy and safety of tadalafil for erectile dysfunction in patients with multiple sclerosis.
Topics: Carbolines; Humans; Impotence, Vasculogenic; Male; Multiple Sclerosis; Phosphodiesterase 5 Inhibitors; Risk Factors; Tadalafil | 2011 |
Dysfunction of the endothelial-platelet pathway in patients with erectile dysfunction before and after daily treatment with tadalafil.
Topics: Carbolines; Cell-Derived Microparticles; Endothelium, Vascular; Erectile Dysfunction; Humans; Impotence, Vasculogenic; Integrin alphaVbeta3; Male; Middle Aged; Tadalafil | 2012 |
New immunophenotype of circulating endothelial progenitor cells and endothelial microparticles in patients with erectile dysfunction and metabolic syndrome: effects of tadalafil administration.
Topics: Analysis of Variance; Antigens, CD; Antigens, CD34; Cadherins; Carbolines; Cell-Derived Microparticles; Endothelial Cells; Flow Cytometry; Humans; Immunophenotyping; Impotence, Vasculogenic; Italy; Leukocyte Common Antigens; Male; Metabolic Syndrome; Middle Aged; Phenotype; Phosphodiesterase 5 Inhibitors; Stem Cells; Tadalafil; Treatment Outcome | 2011 |
[Risk classification assures safety].
Topics: Carbolines; Clinical Trials as Topic; Contraindications; Diabetic Angiopathies; Heart Diseases; Humans; Hypertension; Impotence, Vasculogenic; Male; Phosphodiesterase Inhibitors; Risk Assessment; Tadalafil | 2003 |
Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection.
Topics: Animals; Blotting, Western; Carbolines; Denervation; Fibrosis; Impotence, Vasculogenic; Male; Muscle, Smooth; Penis; Phosphodiesterase Inhibitors; Prostatectomy; Rats; Rats, Sprague-Dawley; Tadalafil | 2008 |